Background: Dermoscopic evaluation of pigmented lesions includes assessment of criteria suggestive of melanocytic proliferation. Dermoscopic diagnosis may be hampered when a nonmelanocytic lesion displays one or more melanocytic features.
Objective: To evaluate the incidence of misleading dermoscopic features characteristic of melanocytic lesions in pigmented seborrheic keratosis (PSK).
Methods: We evaluated 402 clinically typical PSKs from 138 patients with at least one clinically identifiable PSK.
Results: Approximately 10% of PSKs displayed one or more melanocytic features, the most frequent being a "false" pigment network.
Conclusion: The occurrence of a "false" pigment network in PSK can be misleading in the differential diagnosis of clinically equivocal lesions. A correct diagnosis can only be obtained if all available dermoscopic criteria are appropriately assessed together with the clinical examination.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1046/j.1524-4725.2002.02002.x | DOI Listing |
Med J Malaysia
January 2025
Department of General Surgery, Saveetha Medical College and Hospital, Saveetha Institute of Medical and Technical Sciences (SIMATS), Saveetha University, Thandalam, Chennai, Tamil Nadu, India.
Seborrheic keratosis (SK) is a prevalent hyperkeratotic dermatological condition characterized by benign proliferation of epidermal keratinocytes, typically occurring in the middle to advanced stages of life. While the trunk is the primary site for lesions, they can also manifest on the extremities, face, and scalp. Although SK is typically benign, there can be morphological overlap with malignant skin lesions, necessitating meticulous differentiation for an accurate diagnosis.
View Article and Find Full Text PDFDiagnostics (Basel)
November 2024
Ophthalmology Unit, Department of Medicine, Surgery and Neuroscience, University of Siena, 53100 Siena, Italy.
Pediatr Dermatol
November 2024
Ronald O. Perelman Department of Dermatology, New York University Grossman School of Medicine, New York, New York, USA.
Background: Binimetinib and selumetinib are two mitogen-activated protein kinase kinase (MEK) inhibitors used to treat low-grade gliomas and plexiform neurofibromas. Cutaneous toxicities are commonly associated with MEK inhibitors; however, limited studies have examined cutaneous effects in a pediatric population or whether toxicities vary between MEK inhibitors.
Methods: We conducted an IRB-approved, single-center, retrospective review of pediatric neuro-oncology patients on binimetinib or selumetinib who presented to NYU from April 2016 through July 2022.
Sci Rep
October 2024
Enspectra Health, Inc., Mountain View, CA, USA.
Biopsy-based histology has been the foundation of disease diagnosis and management for over a century. A long-sought goal in dermatology is the development of an imaging modality with sufficient resolution and compositional detail to noninvasively interrogate skin histology in vivo. Here, we describe a system that achieves this goal using cross-sectionally scanned, multimodal microscopy (cross-modal).
View Article and Find Full Text PDFBioengineering (Basel)
October 2024
Dermatology Unit, Department of Medicine, Surgery and Neuroscience, University of Siena, 53100 Siena, Italy.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!